Document:

Execution
Version

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

SUBLICENSE
AGREEMENT

 

THIS
SUBLICENSE Agreement (“Agreement”) is entered into on September 26, 2017 (the “Effective
Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue,
Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation,
having its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).

 

WITNESSETH

 

WHEREAS,
pursuant to an exclusive license agreement between ReCyte, Inc., formerly Embryome Sciences, Inc., with the Advanced Cell Technology,
Inc (“ACT”), dated July 10, 2008, as amended and August 15, 2008 (the “ACT Licenses”), BioTime
has obtained rights for Patent Rights and Know-How;

 

WHEREAS,
AgeX is an Affiliate of BioTime; and

 

WHEREAS,
AgeX wishes to obtain from BioTime a license under certain rights for the Patent Rights and Know-How, and BioTime is willing to
grant such a license upon the terms and conditions hereinafter set forth.

 

NOW
THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree
as follows:

 

NOW
THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree
as follows:

 

ARTICLE
1. DEFINITIONS

 

1.1
“Affiliate” means with respect to any Person (including but not limited to BioTime, AgeX or a Third
Party) any corporation, limited liability company, limited partnership or other entity in control of, controlled by, or under
common control with such Person.

 

1.2
“AgeX Field” means all uses for the treatment, palliation, diagnosis, or prevention of any disease,
disorder or health condition excluding the BioTime Exclusive Field.

 

1.3
“AgeX Non-Exclusive Field” means products, medical devices, and services for the prevention, treatment,
amelioration, diagnosis or monitoring of disorders, degeneration, congenital conditions, or injuries of tendon.

 

    	 

    	Execution Version

    

 

1.4
“BioTime Exclusive Field” means products, medical devices, and services for the prevention, treatment,
amelioration, diagnosis or monitoring of (a) orthopedic indications, meaning [***]; (b) ophthalmological indications, meaning
[***]; and (c) medical aesthetics meaning [***].

 

1.5
“BioTime Non-Exclusive Field” means products, medical devices, and services for the prevention, treatment,
amelioration, diagnosis or monitoring of disorders, degeneration, congenital conditions, or injuries of tendon. For the avoidance
of doubt, the BioTime Non-Exclusive Field does not include the prevention, treatment, amelioration, diagnosis or monitoring of
disorders, degeneration, congenital conditions, or injuries of an orthopedic indication.

 

1.6
“Cells or Cell Lines” means the cells and cell lines identified in Exhibit A or Exhibit B attached hereto
that are covered by (i.e., made or developed using) the Patent Rights or Know-How and/or are provided to AgeX by BioTime.

 

1.7
“Change of Control” means the occurrence of any of the following: (a) any consolidation or merger of
AgeX with or into any Third Party, or any other corporate reorganization involving a Third Party, in which those persons or entities
that are stockholders of AgeX immediately prior to such consolidation, merger or reorganization own less than fifty percent (50%)
of the surviving entity’s voting power immediately after such consolidation, merger or reorganization; (b) a change in the
legal or beneficial ownership of fifty percent (50%) or more of the voting securities of AgeX (whether in a single transaction
or series of related transactions) where, immediately after giving effect to such change, the legal or beneficial owner of more
than fifty percent (50%) of the voting securities of AgeX is a Third Party; or (c) the sale, transfer, lease, license or other
disposition of all or substantially all of AgeX’s assets or business in one or a series of related transactions to a Third
Party.

 

1.8
“Combination Product” means a product that contains a Licensed Product component and at least one other
component that has independent research, diagnostic or therapeutic utility, could reasonably be sold separately and has economic
value of its own.

 

1.9
“Commercialization” in respect of a particular product, any and all activities (whether before or after
receipt of marketing approval in respect of the product, medical device or service) directed to the marketing, detailing and promotion
of the product or medical device after marketing approval for such product has been obtained, and includes marketing, promoting,
detailing, distributing, offering to commercially sell and commercially selling the product, medical device or service, importing,
exporting or transporting the product or medical device for commercial sale, and regulatory affairs with respect to the foregoing.
When used as a verb, “Commercializing” means engaging in Commercialization and “Commercialize”
and “Commercialized” shall have corresponding meanings.

 

1.10
“Commercially Reasonable Efforts” means, with respect to the efforts to be expended by any party and
with respect to any objective, the reasonable, diligent, good faith efforts to accomplish such objective as such party would use
in its ordinary course of business to accomplish a similar objective under similar circumstances. With respect to any objective
relating to the research, development, or exploitation as used herein, “Commercially Reasonable Efforts” means that
level, caliber and quality of efforts and resources reasonably and normally used in the Research, Development and Exploitation
by biopharmaceutical companies for a product that is of similar market potential and at a similar stage in its Development or
product life, taking into account, without limitation, issues of safety, efficacy, product profile, competitiveness in the marketplace,
including efforts used by similarly positioned competitors for competing products, regulatory structure involved, optimal timing
for market entry, proprietary position, and other relevant scientific, technical, business, marketing, return on investment, financial
resources, and other commercial factors. Without limiting the generality of the foregoing, “Commercially Reasonable Efforts,
as it applies to the financial matters herein, means adherence to the budgeting and staffing targets and timelines (to the extent
adherence to such activities and timelines are controllable by the party responsible for performing such activities).

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

1.11
“Confidential Information” means all information and know-how and any tangible embodiments thereof provided
by or on behalf of one party to the other party either in connection with the discussions and negotiations pertaining to this
Agreement or in the course of performing under this Agreement, which may include data, knowledge, practices, processes, ideas,
research plans, formulation or manufacturing processes and techniques, scientific, manufacturing, marketing and business plans,
and financial and personnel matters relating to the disclosing party or to its present or future products, sales, suppliers, customers,
employees, investors or business; provided, that, information or know-how of a party will not be deemed Confidential Information
of such party for purposes of this Agreement if such information or know-how: (a) was already known to the receiving party, other
than under an obligation of confidentiality or non-use, at the time of disclosure to such receiving party, as can be shown by
written records; (b) was generally available or known to parties reasonably skilled in the field to which such information or
know-how pertains, or was otherwise part of the public domain, at the time of its disclosure to such receiving party; (c) became
generally available or known to parties reasonably skilled in the field to which such information or know-how pertains, or otherwise
became part of the public domain, after its disclosure to such receiving party through no fault of the receiving party; (d) was
disclosed to such receiving party, other than under an obligation of confidentiality or non-use, by a Third Party who had no obligation
to the disclosing party not to disclose such information or know-how to others, as can be shown by written records; or (e) was
independently discovered or developed by such receiving party, as can be shown by its written records, without the use or benefit
of, or reliance on, Confidential Information belonging to the disclosing party.

 

1.12
“Control” means, with respect to any Patent(s), possession of the right, whether directly or indirectly,
and whether by ownership, license or otherwise, to grant a license, sublicense or other right to or under such Patent(s) as provided
for herein.

 

1.13
“Cover” means that a product or service, when made, used, or sold, or that a method, procedure, process,
when practiced, would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of any claim
or claims included within the Patent Rights.

 

1.14
“Development” means all activities related to stability testing, process development, formulation, manufacturing
scale-up, qualification and validation, quality assurance/quality control, clinical studies, including manufacturing in support
thereof, statistical analysis and report writing, the preparation pre-submission and submission of INDs, premarket approvals,
510(k)s, NDAs, BLAs, and other regulatory applications, filings or submissions, regulatory affairs with respect to the foregoing,
and all other activities necessary or reasonably useful or otherwise requested or required by the United States Food and Drug
Administration, or any successor agency (“FDA”) or a comparable foreign regulatory authority as a condition
or in support of obtaining or maintaining a regulatory marketing approval, or an approval for a clinical trial, anywhere in the
world. When used as a verb, “Develop” means to engage in Development.

 

    	 

    	Execution Version

    

 

1.15
“Development Costs” means, subject to the other terms of this Agreement and without duplication, (a)
the [***] by or on behalf of AgeX or any of its Affiliates, during the term of and pursuant to this Agreement, that (i) are [***],
and (ii) [***] of the sublicense in which the designation was made.

 

1.16
“Effective Date” has the meaning set forth in the opening paragraph of this Agreement.

 

1.17
“Exploit” means, to Develop, Manufacture, Commercialize, make, have made, use, offer to sell, sell or
import; and “Exploitation” means Developing, Manufacturing, Commercializing, making, having made, using,
offering to sell, selling or importing.

 

1.18
“Know-How” means all compositions of matter, techniques and data and other knowhow and technical information
including inventions (whether or not patentable), improvements and developments, practices, methods, concepts, trade secrets,
documents, computer data, computer slide illustrations, computer code, apparatus, test data, analytical and quality control data,
formulation, manufacturing, patent data or descriptions, development information, drawings, specifications, designs, plans, proposals
and technical data .and manuals and all other Confidential Information that is owned or controlled by BioTime as of the Effective
Date, and that specifically relates to the subject matter (a) described in or claimed by the Patent Rights, (b) described in or
claimed by the abandoned provisional applications including but not limited to: [***] .

 

1.19
“Licensed Process” means any process or method, the development, use, practice, or sale of which (a)
is covered in whole or in part by, or cannot be performed without infringing, a Valid Claim of the Patent Rights in the country
in which such Licensed Process is practiced or sold, (b) uses Cells or Cell Line listed in Exhibit A, or (c) otherwise utilizes
the Know-How.

 

1.20
“Licensed Product” means any product, or part thereof or derived therefrom, the development, manufacture,
sale, lease, or use of which (a) is covered in whole or in part by, or cannot be performed without infringing, a Valid Claim of
the Patent Rights in the country in which any such product or part thereof is developed, made, used, sold or imported by AgeX,
(b) uses Cells or Cell Line listed in Exhibit A, or (c) otherwise utilizes the Know-How.

 

1.21
“Licensed Services” means any service, the development, use, performance, or sale of which is covered
in whole or in part by, or cannot be performed without infringing, a Valid Claim of the Patent Rights in the country in which
any such service is so developed, used, performed, sold, offered for sale, imported or exported by AgeX or otherwise utilizes
the Know-How.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

1.22
“Manufacture” and “Manufacturing” means, in respect of a particular pharmaceutical,
bio-pharmaceutical, diagnostic, or prognostic product, and without limitation, all activities related to the production, manufacture,
processing, formulation, filling, finishing, packaging, labeling, shipping, handling, holding, storage and warehousing of such
product or any intermediate thereof, including process development, process qualification and validation, scale-up, pre-clinical,
clinical and commercial manufacture and analytic development, product characterization, stability testing, quality assurance and
quality control.

 

1.23
“Net Sales” means the invoiced amount on sales by AgeX or its Affiliates or Sublicensees of Licensed
Products, Licensed Services or Licensed Processes less (to the extent applicable and appropriately documented) (i) sales, tariff
and import duties, use and other taxes directly imposed with reference to particular sales, (ii) discounts, rebates, and similar
credits and charge backs actually allowed and taken (regardless of whether taken or paid at the time of sale or paid or credited
to the buyer at a subsequent date), and (iii) amounts allowed or credited on returns; provided, any such allowed deductions shall
be listed on the invoice for the applicable Licensed Product, Licensed Process or Licensed Service or otherwise documented in
the ordinary course of business. In the case of Combination Products, Net Sales means the total invoice amount earned on sales
of Combination Products by AgeX or its Affiliates to any third person or entity, less, to the extent applicable, the deductions
set forth above, multiplied by a proration factor that is determined as follows:

 

a)
If all components of the Combination Product were sold separately during the same or immediately preceding calendar quarter, the
proration factor shall be determined by the formula [***]; or

 

b)
if all components of the Combination Product were not sold separately during the same or immediately preceding calendar quarter,
the proration factor shall be determined by the formula [***].

 

1.24
“Patent Rights” means the patents and patent applications identified on Exhibit C attached hereto, and
any divisional, continuation or continuation-in-part of those applications, but only to the extent the claims in said applications
are directed to subject matter specifically described in the patents and patent applications identified on Exhibit C, as well
as any patents issued on these patent applications, and any reissues, reexaminations, extensions and substitutions (or the equivalent)
thereof and any foreign counterparts to those patents and patent applications. The parties agree that Exhibit C may be revised
from time to time after the Effective Date to reflect changes thereto.

 

1.25
“Person” means any individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint
venture or other similar entity or organization, including a government or political subdivision, department or agency of a government.

 

1.26
“Research” means performance of scientific experiments to answer questions not answerable or easily
answerable through the published scientific literature, pre-clinical and other non-clinical testing, test method development,
and toxicology, formulation, and process development work.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

1.27
“Sublicensee” means a Person, other than an Affiliate, that is granted a sublicense by a Party under
the license grants hereunder.

 

1.28
“Sublicensing Consideration” has the means the royalties payable pursuant to Section 2.3(d).

 

1.29
“Territory” means worldwide, where patent coverage applies.

 

1.30
“Third Party” means any Person other than AgeX, BioTime, or their respective Affiliates.

 

1.31
“Valid Claim” means (a) a claim of any issued and unexpired United States or foreign patent included
in the Patent Rights which has not lapsed or become abandoned or been declared invalid or unenforceable by a court of competent
jurisdiction or an administrative agency from which no appeal can be or has been taken within the time allowed from such appeal
and which has not been disclaimed or determined to be invalid or unenforceable through reissue, disclaimer· or otherwise,
or (b) to the extent rights are granted by a governmental patent authority thereunder (i.e., to the extent that the owner would
be able to enforce a right to a patent royalty thereunder under applicable patent law), a claim of a pending patent application
included in the Patent Rights..

 

ARTICLE
2. LICENSE GRANT AND RELATED OBLIGATIONS

 

2.1
License Grant. Subject to the terms and conditions set forth herein, and subject the rights granted by and to ACT, Third
Parties or any Affiliates prior to the Effective Date, BioTime hereby grants to AgeX a royalty-bearing exclusive license, in the
AgeX Field and a nonexclusive license in the AgeX Non-Exclusive Field in the Territory to use the Patent Rights and Know-How to
(a) Research, Develop, Exploit, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported,
export and have exported Licensed Products, (b) Research, Develop, Exploit, use, practice, sell, have sold, offer for sale, have
offered for sale, import, have imported, export and have exported Licensed Processes, (c) develop, use, perform, sell, have sold,
offer for sale, have offered for sale, import, have imported, export and have exported Licensed Services, and (d) Research using
Cells or Cell Lines listed in Exhibit B.

 

2.2
BioTime shall, and hereby does, grant AgeX, subject to the terms and conditions of Section 2.1, and subject the rights granted
to ACT, Third Parties or any Affiliates, a license to any new Licensed Patents created after the Effective Date that cover Licensed
Products, Licensed Processes, and Licensed Services, in the AgeX Field and the AgeX Non-Exclusive Field in the Territory, to (a)
Research, Develop, Exploit, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported,
export and have exported Licensed Products, (b) Research, Develop, Exploit, use, practice, sell, have sold, offer for sale, have
offered for sale, import, have imported, export and have exported Licensed Processes, (c) develop, use, perform, sell, have sold,
offer for sale, have offered for sale, import, have imported, export and have exported Licensed Services, and (d) Research using
Cells or Cell Lines listed in Exhibit B, from the Effective Date for a period of ten (10) years.

 

    	 

    	Execution Version

    

 

2.3
Sublicensing. The rights and licenses granted by BioTime to AgeX under Sections 2.1 and 2.2 shall include the right to
grant Sublicenses (or further rights of reference) through multiple tiers of Sublicensees, subject to the following:

 

a)
The terms of any such sublicense or further rights of reference shall be in accordance with the terms and conditions of this Agreement
and the ACT Licenses. With regard to all Sublicenses granted by AgeX pursuant to the rights granted to it by BioTime under this
Agreement, (i) AgeX may not grant to any Sublicensee any right to maintain BioTime Licensed Patents, defend claims brought by
Third Parties, or commence any legal action against any Third Party for infringement of BioTime Licensed Patents and (ii) AgeX
shall notify BioTime of AgeX’s intent to enter into a sublicense and shall (1) provide BioTime with a draft of the proposed
sublicense not later than [***] days before such sublicense is executed and BioTime shall have the right to provide a copy of
such draft to ACT, (2) to allow BioTime and ACT to comment on the terms of the sublicense if BioTime or ACT chooses to comment,
and (3) provide BioTime with a fully executed copy of all sublicense agreements within [***] days after execution and BioTime
shall have the right to provide a copy thereof to ACT;;

 

b)
Notwithstanding the grant of any such sublicense or further rights of reference hereunder, AgeX shall remain solely responsible
to BioTime for the performance of its obligations under the terms hereof and for any breach of such obligations, whether such
breach shall be caused by AgeX or any Sublicensee; and

 

c)
For the avoidance of doubt it is hereby acknowledged that the appointment by AgeX of any distributor for a Licensed Product, Licensed
Process or Licensed Service the extent permitted herein, or of any Third Party to assist in the Development of a Licensed Product,
Licensed Process or Licensed Service shall not be deemed to constitute the appointment of a Sublicensee or the sublicense by AgeX
of any rights hereunder.

 

d)
Consideration

 

i.
AgeX will pay to BioTime [***] of all Net Sales of a Licensed Product, Licensed Process or Licensed Service by Sublicensees until
the royalty payments to ACT by BioTime total [***]Dollars (U.S.) ($[***]).:After the consideration in Section 2.2(d)(i) is fully
paid, AgeX will pay to BioTime a [***] Royalty on Net Sales of a Licensed Product, Licensed Process or Licensed Service by Sublicensees.
If AgeX is obligated to pay royalties to one or more BioTime Affiliates for the use of other patent rights with respect to the
use, manufacture or sale of a Licensed Product, Licensed Process or Licensed Service and as a result the royalties payable under
this Article plus the royalties payable to BioTime and its Affiliates in the aggregate would exceed [***]of Net Sales, the royalty
due under this Article shall be reduced such that the total amount of royalties payable to BioTime and its Affiliates is [***],
with the allocation of such royalties among BioTime and its Affiliates to be made in accordance with their instructions.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ii.
Sublicensing Consideration. AgeX shall pay to BioTime [***] of any Sublicensing Consideration, including, but not limited to,
upfront payments and milestones, and will include non-cash exchanges or considerations. Sublicensing Consideration does not include
[***]. If AgeX is obligated to pay Sublicensing Consideration to one or more BioTime Affiliates for the use of patent rights with
respect to the use, manufacture or sale of a Licensed Product, Licensed Process or Licensed Service and as a result the Sublicensing
Consideration payable under this Section plus the Sublicensing Consideration payable to BioTime and its Affiliates would exceed
[***] of the Sublicensing Consideration, the Sublicensing Consideration due under this Section may be reduced such that the total
amount of Sublicensing Consideration payable to BioTime and its Affiliates is [***], with the allocation of such Sublicensing
Consideration among BioTime and its Affiliates to be made in accordance with their instructions

 

iii.
Development Funding. Consideration received from a Sublicensee of AgeX that is explicitly designated in the sublicense agreement
to cover Development Costs will not be considered Sublicensing Considering subject to Section 2.2(d) (iii). Any Sublicensing Considering
actually received by AgeX that was designated as Development Costs that were not actually incurred by AgeX as Development Costs
in respect to Development of a Licensed Product, Licensed Service or Licensed Process, will become Sublicensing Consideration
if not returned upon completion or termination of the project for which the consideration was so designated.

 

ARTICLE
3. TERM OF AGREEMENT

 

This
Agreement shall be in full force and effect from the Effective Date until the later of (i) July 10, 2028 or (ii) the end of the
term of the last-to-expire of the Patent Rights licensed under this Agreement unless otherwise terminated by operation of law
or pursuant to the terms of this Agreement.

 

ARTICLE
4. OBLIGATIONS, FEES & ROYALTIES

 

As
additional consideration of the license granted to AgeX from BioTime in Article 2 of this Agreement, AgeX shall pay to BioTime
a royalty equal to [***] of the Net Sales received by AgeX and its Affiliates for all Licensed Products, Licensed Process or Licensed
Service sold, performed, or leased by AgeX or any Affiliate. The obligation of AgeX to pay royalties on Net Sales by AgeX and
its Affiliates (but not on Net Sales received by Sublicensees) shall terminate (a) with respect to Net Sales arising in any country
concurrently with the expiration or termination of the last applicable Valid Claim within the Patent Rights in such country in
which the Licensed Product, Licensed Process or Licensed Service is, (as applicable), performed, sold, leased, or manufactured,
or in which the Patent Rights are licensed, and (b) in any and all cases when royalty payments to ACT by BioTime total [***] (U.S.)
($[***]). If AgeX is obligated to pay royalties to one or more BioTime Affiliates for the use of other patent rights with respect
to the use, manufacture or sale of a Licensed Product, Licensed Process or Licensed Service and as a result the royalties payable
under this Article plus the royalties payable to BioTime and its Affiliates in the aggregate would exceed [***] of Net Sales,
the royalty due under this Article shall be reduced such that the total amount of royalties payable to BioTime and its Affiliates
is [***] with the allocation of such royalties among BioTime and its Affiliates to be made in accordance with their instructions.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
5. COMMERCIAL DILIGENCE & MILESTONES

 

5.1
Commercial Diligence. AgeX shall use commercially reasonable and diligent efforts to bring one or more Licensed Products,
Licensed Processes and Licensed Services to market through an active and diligent program for exploitation of the Patent Rights
and Know-How and to continue active, diligent marketing efforts for one or more Licensed Products, Licensed Processes and Licensed
Services throughout the life of this Agreement.

 

ARTICLE
6. CONFIDENTIALITY

 

6.1
During the course of this Agreement, BioTime and AgeX may provide each other with Confidential Information. Confidential Information
may be disclosed in oral, visual or written form, and includes such information that is designated in writing as such by the discloser
at the time of disclosure, orally disclosed information that is designated in writing as confidential within 30 days after such
oral disclosure, or information which, under all of the given circumstances ought reasonably be treated as Confidential Information
of the disclosing party. BioTime and AgeX each intend to maintain the confidential or trade secret status of their Confidential
Information. Each shall exercise reasonable care to protect the Confidential Information of the other from disclosure to third
parties; no such disclosure shall be made without the other’s written permission. Upon termination or expiration of this
Agreement, BioTime and/or AgeX shall comply with the other’s written request to return all Confidential Information that
is in written or tangible form. Except as expressly provided herein, neither BioTime nor AgeX is granted any license to use the
other’s Confidential Information. The obligations of BioTime and AgeX under this Article 6, shall survive any expiration
or termination of this Agreement. Notwithstanding the preceding provisions of this Section 6.1, until such time as this Agreement
is terminated: (a) Know How and the content of any patent application relating to or included in Patent Rights shall be deemed
to be the AgeX’s Confidential Information rather than BioTime’s Confidential Information; (b) AgeX shall have the
right to disclose Know How and the content of patent applications related to or included in Patent Rights to third parties without
restriction under this Agreement; and (c) AgeX shall not have any obligation to BioTime to treat Know How or the content of any
patent application related to or included in Patent Rights as BioTime’s Confidential Information.

 

6.2
The parties agree that the specific terms (but not the overall existence) of this Agreement shall be considered Confidential Information;
provided, however, that the parties may disclose the terms of this Agreement to investors or potential investors, potential business
partners, potential co-developers, manufactures, marketers, or distributors of any Licensed Product, Licensed Process, or Licensed
Service, and in any prospectus, offering, memorandum, or other document or filing required by applicable securities laws or other
applicable law or regulation. The parties may also disclose Confidential Information that is required to be disclosed to comply
with applicable law or court order, provided that the recipient gives reasonable prior written notice of the required disclosure
to the discloser and reasonably cooperates with the discloser’s efforts to prevent such disclosure.

 

    	 

    	Execution Version

    

 

ARTICLE
7. QUARTERLY & ANNUAL REPORTS

 

7.1
AgeX shall maintain complete and accurate records of Licensed Products, Licensed Services and Licensed Processes that are sold,
performed, or, leased by AgeX or its Affiliate under this Agreement, and all Sublicense Revenue received by AgeX and its Affiliates.
AgeX shall keep, and shall cause its Affiliates to keep, full, true and accurate books of account containing all particulars that
may be necessary for the purpose of showing the amounts payable to BioTime hereunder and AgeX’s compliance with the terms
and conditions of this Agreement. Said books of account shall be kept at AgeX’s principal place of business or at such other
location as may be agreed upon by the parties. Said books and the supporting data shall be open upon reasonable advance notice
(and no more frequently than once per calendar year) for three (3) years following the end of the calendar year to which they
pertain, to the inspection of BioTime or its agents for the purpose of verifying AgeX’s royalty statement or compliance
in other respects with this Agreement. If any such audit determines that the reported payments to BioTime were less than [***]
of the actual amount due to BioTime for the period in question, AgeX shall bear the cost of such audit (without limiting BioTime’s
other remedies with respect thereto).

 

7.2
After the first commercial sale of a Licensed Product, Licensed Service or Licensed Process by AgeX or any Affiliate, within thirty
(30) days after March 31, June 30, September 30 and December 31, of each year, shall deliver to BioTime a true and accurate report
of all Net Sales and License Revenue during the preceding three-month period under this Agreement as shall be pertinent to a royalty
accounting hereunder. Each such report shall include at least the following:

 

a)
number(s) and type(s) of Licensed Products, Licensed Processes and Licensed Services sold, leased, or performed by AgeX and/or
its Affiliates;

 

b)
total billings and payments received for Licensed Products, Licensed Processes and Licensed Services performed, sold, or leased
by AgeX and its Affiliates; and

 

c)
deductions applicable as provided in Section 1.25;

 

7.3
each such report submitted, AgeX shall pay to BioTime the royalties and other payments due and payable under this Agreement. If
no royalties or other payments shall be due, AgeX shall so report.

 

7.4
AgeX’s reporting obligations hereunder shall terminate when AgeX’s obligation to pay royalties and sublicensi

 

ARTICLE
8. PAYMENTS, RECORDS AND AUDITS

 

8.1
Payments. AgeX shall pay all royalties accruing to BioTime in U.S. Dollars, without deduction of exchange, collection,
wiring fees, bank fees, or any other charges, within [***] following the calendar quarter in which Net Sales occur. All payments
to BioTime will be made in United States dollars by wire transfer or check payable to “BioTime, Inc.” and sent to:

 

BioTime,
Inc.

 

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention:
Accounts Payable

Email:
ap@biotimeinc.com

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

8.2
Late Payments. In the event any payments or other fees are not received by BioTime
when due hereunder, AgeX shall pay to BioTime interest charges at the rate of [***] on
the amount of such payments or fees that were not paid by the date due for the reporting period.

 

8.3
Foreign Exchange. With respect to Net Sales invoiced in a currency other than U.S. dollars, such Net Sales will
be converted into the U.S. dollar equivalent using the average conversion rate existing in the United States (as reported in The
Wall Street Journal, New York edition) during the applicable calendar quarter. If The Wall Street Journal ceases to be published,
then the rate of exchange to be used shall be that reported in such other business publication of national circulation in the
United States on which the parties reasonably agree.

 

8.4
Blocked Currency. In each country where the local currency is blocked and cannot be removed from the country, payments
under this Agreement arising from activities in that country for which AgeX, or an Affiliate thereof, does not receive payment
in U.S. currency, freely useable outside of such country, shall, notwithstanding anything to the contrary, be paid to BioTime
in U.S. Dollars

 

8.5
Records. AgeX shall keep, and cause its Affiliates, to keep, complete, true and accurate records and books containing all
particulars that may be necessary for the purpose of showing the amounts payable to BioTime hereunder. Records and books shall
be kept at AgeX’s principle place of business or the principal place of business of the appropriate division of AgeX to
which this Agreement relates.

 

8.6
Audit. Said books and the supporting data shall be open at all reasonable times for five (5) years following the end of
the calendar year to which they pertain, to inspection by BioTime, or its agents, upon reasonable prior notice to AgeX, for the
purpose of verifying AgeX’s royalty statement or compliance in other respects with this Agreement. Such access will be available
to BioTime upon not less than ten (10) days written notice to AgeX, not more than once each calendar year of the Term for BioTime,
during normal business hours, and once a year for BioTime for three years after the expiration or termination of this Agreement.
Should such inspection lead to the discovery of a greater than [***], discrepancy in reporting to BioTime’s detriment, AgeX
agrees to pay the full cost of such inspection. Whenever AgeX has its books and records audited by an independent certified public
accountant, AgeX will, within fifteen (15) days of the conclusion of such audit, provide BioTime with a written statement, certified
by said auditor, setting forth the calculation of royalties due to BioTime over the time period audited as determined from the
books and records of AgeX.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
9. PATENT PROSECUTION, MAINTENANCE, AND DEFENSE

 

9.1
Prosecution, Maintenance, and Defense. BioTime will, as allowed under the ACT Licenses, (i) use Commercially Reasonable
Efforts to prosecute and maintain the Patent Rights, and (ii) control all prosecution, filing, and defense of the Patent Rights,
provided that BioTime will use Commercially Reasonable Efforts to provide AgeX copies of documents prepared by or received from
patent counsel related to the prosecution and/or maintenance of the Patent Rights to AgeX for review and comment prior to filing
to the extent practicable under the circumstances.

 

9.2
Patent Expenses. AgeX will be billed and will pay [***] of all reasonable, documented costs and fees and other charges
incurred by BioTime with respect to the preparation, prosecution, maintenance, and defense of the Patent Rights that are primarily
related to the AgeX Field, within thirty (30) days of receipt of invoice from the selected patent attorney or from BioTime.

 

9.3
Enforcement of the Patent Rights. The Parties agree to notify each other in writing of any actual or threatened infringement
by a third party of the Patent Rights or of any third-party claim of invalidity or unenforceability of the Patent Rights, or of
any interference or other proceeding affecting the Patent Rights. BioTime shall have the first right to prosecute and defend such
claims.

 

9.4
Cooperation. BioTime and AgeX agree to reasonably cooperate in connection with the preparation, filing, prosecution, and
maintenance of the Patent Rights. Cooperation includes, without limitation, (a) promptly executing all papers and instruments
or requiring employees of BioTime or AgeX to execute papers and instruments as reasonably appropriate to enable BioTime to file,
prosecute, and maintain Patent Rights in any country; and (b) promptly informing BioTime of matters that may affect preparation,
filing, prosecution, or maintenance of Patent Rights (such as becoming aware of an additional inventor who is not listed as an
inventor in a patent application).

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

9.5
New Patents, Inventions, and Discoveries.

 

a)
AgeX shall have the right to file and prosecute new patent applications (and to obtain new patents) covering Licensed Products,
Licensed Processes, and Licensed Services, and any other subject matter, with respect to any Know How and any other technology,
invention, or discovery made by AgeX or any of its Affiliates using Patent Rights and Know How. AgeX shall, and hereby does, grant
BioTime an exclusive license to the new patents in the BioTime Exclusive Field and a nonexclusive license in the BioTime Non-Exclusive
Field developed from the Effective Date for a period of [***].

 

b)
AgeX and BioTime shall jointly file and prosecute new applications covering Licensed Products, Licensed Processes, and Licensed
Services, and any other subject matter, with respect to any Know-How and any other technology, invention, or discovery made jointly
by AgeX and BioTime using Patent Rights and/or Know-How. The Parties will share in the costs for filing, and prosecuting any jointly
owned inventions relating to Licensed Products, Licensed Processes, and Licensed Services and any other subject matter, with respect
to any Know-How and any other technology, invention, or discovery using Patent Rights and/or Know-How.

 

9.6
Patent Challenge. In the event AgeX, or its Affiliate(s) challenges the validity, enforceability or scope of any of any
Patent Right or claims thereof by legal or administrative action or proceeding or otherwise, or causes or enables any Third Party
to undertake such a challenge (a “Patent Challenge”):

 

(a)
BioTime shall be entitled to terminate this Agreement on written notice to AgeX;

 

(b)
AgeX shall provide [***] prior written notice of such Patent Challenge and provide BioTime all materials, information, opinions,
and analyses to be used to support such challenge;

 

(c)
AgeX shall promptly reimburse all costs and expenses (including attorneys’ fees) incurred by or on behalf of BioTime with
respect to any defense against such Patent Challenge; and

 

(d)
all amounts due or payable under ARTICLE 4 will be doubled with respect to any payments due or triggered during the pendency of
any Patent Challenge. If the outcome of such Patent Challenge is a determination against the party or parties making, causing,
or enabling such Patent Challenge (the “Challenging Party”), such payments shall remain at such doubled
amount for the remainder of the Term. If the outcome of such Patent Challenge is a determination in favor of the Challenging Party,
AgeX will have no right to recoup any amounts paid under this Agreement before or during the pendency of such Patent Challenge.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
10. PATENT MARKING

 

AgeX
shall permanently and legibly mark all AgeX Products made, used, sold, or otherwise disposed of by AgeX, any Affiliate thereof,
, or their containers, (i) in accordance with patent notice appropriate under Title 35, United States Code or any similar law
in any foreign jurisdiction and (ii) with any other notice of patent rights reasonably necessary, in any country where AgeX Products
are sold, to (a) enable Patent Rights (to the extent, in each case, relating to AgeX Products) to be enforced to their full extent
or (ii) ensure the availability of all potential legal or equitable remedies with respect to any infringement of any Patent Rights
(to the extent, in each case, relating to AgeX Products) by any Third Party.

 

ARTICLE
11. TERMINATION BY BIOTIME

 

11.1
BioTime may terminate this Agreement and the rights, privileges and license granted hereunder by written notice upon a breach
or default of this Agreement by AgeX, as follows:

 

a)
non-payment of any amounts due which is not cured within [***] of receipt of written notice of such non-payment wherein said notice
is delivered by registered mail; or

 

b)
breach of any obligation which is not cured within [***] of a written request to remedy such breach wherein said request is delivered
by registered mail, or if the breach cannot be cured within said [***] period, failure of AgeX within said [***] period to proceed
with reasonable promptness thereafter to cure the breach.

 

11.2
Such termination under 11.1(a) or 11.1(b) shall become automatically effective unless AgeX shall have cured any such material
breach or default prior to the expiration of the applicable cure period.

 

11.3
AgeX shall have the right to terminate this Agreement at any time on [***] prior notice to BioTime, and upon payment of all amounts
due BioTime through the effective date of the termination.

 

11.4
Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation
that matured prior to the effective date of such termination; and Article 6, Article 9, Article 12, and any other Sections or
provisions which by their nature are intended to survive termination, shall survive any such termination.

 

11.5
Obligations After Termination. No termination of this Agreement by BioTime shall relieve AgeX of its obligation to pay any monetary
obligation due or owing at the time of such termination and shall not impair any accrued right of BioTime. AgeX shall pay all
attorneys’ fees and costs incurred by BioTime in enforcing any obligation of AgeX or accrued right of BioTime.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
12. DISPOSITION OF LICENSED PRODUCTS ON HAND

 

Upon
expiration or termination of this Agreement by either party, AgeX shall provide BioTime with a written inventory of all AgeX Products
in process of manufacture, in use or in stock. AgeX may dispose of any such AgeX Products within the [***] period following such
expiration or termination, provided, however, that AgeX shall pay royalties and render reports to BioTime thereon in the manner
specified herein.

 

ARTICLE
13. WARRANTY BY BIOTIME

 

13.1
Right to License. BioTime warrants that it has the lawful right to grant the license set forth in this Agreement.

 

13.2
EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, BIOTIME, ITS DIRECTORS, OFFICERS, AGENTS, SHAREHOLDERS, EMPLOYEES,
AND AFFILIATES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
TO WARRANTIES OF MERCHANT ABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND
THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION
MADE OR WARRANTY GIVEN BY BIOTIME THAT THE PRACTICE BY AGEX OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS
OF ANY THIRD PARTY. IN NO EVENT SHALL BIOTIME, ITS DIRECTORS, OFFICERS, AGENTS, SHAREHOLDERS, EMPLOYEES AND AFFILIATES BE LIABLE
FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS
OF WHETHER BIOTIME SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY OF SUCH DAMAGES.

 

13.3
AgeX agrees to maintain insurance or self-insurance that is reasonably adequate to fulfill any potential obligation to the indemnified
parties. AgeX shall continue to maintain such insurance or self-insurance during the term of this Agreement and after the expiration
or termination of this Agreement for a period of five (5) years.

 

13.4
Limitations. Nothing in this Agreement shall be construed as:

 

a)
a warranty or representation by BioTime as to the validity or scope of any Patent Rights.

 

b)
a warranty or representation by BioTime that anything made, used, sold or otherwise disposed of pursuant to any license granted
under this Agreement is or will be free from infringement of intellectual property rights of third parties.

 

c)
an obligation by BioTime to bring or prosecute actions or suits against third parties for patent infringement, except as may expressly
be provided in ARTICLE 14 hereof.

 

d)
conferring by implication, estoppel or otherwise any license or rights under any patents of BioTime other than Patent Rights.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
14. INFRINGEMENT

 

14.1
Knowledge of Infringement. If either party learns of a claim of infringement of or by any Patent Rights with respect to
the rights licensed to AgeX under this Agreement, that party shall give written notice of such claim to the other party. BioTime
shall, as between the parties, have the sole and exclusive right to prosecute or terminate such infringement or otherwise enforce
the Patent Rights against any such infringer. AgeX may not bring suit for any infringement of the Patent Rights without BioTime’s
prior written consent. No settlement, consent judgment or other voluntary final disposition of any suit with respect to any infringement
of any Patent Right may be entered into without the consent of BioTime.

 

14.2
Expense and Proceeds from Legal Action. Any legal action concerning any infringement of the rights to Patent Rights granted
hereunder shall be at the expense of the party by whom suit is filed, hereinafter referred to as the “Litigating Party”.
Any damages or costs recovered by the Litigating Party in connection with any such legal action filed by it hereunder, and remaining
under the Litigating Party is reimbursed for its costs and expenses reasonably incurred in the lawsuit, and after any royalties
or other payments due to BioTime under ARTICLE 4 are paid, shall be divided as follows: [***] of such damages or recoveries concerning
the infringement of rights granted to AgeX hereunder to AgeX, with BioTime retaining the remainder.

 

14.3
Cooperation in Litigation Proceedings. AgeX and BioTime shall reasonably cooperate with each other in litigation proceedings
instituted hereunder, provided that such cooperation shall be at the expense of the Litigating Party, and such litigation shall
be controlled by the Litigating Party.

 

ARTICLE
15. INSURANCE

 

15.1
Insurance Requirements. Beginning at the time any AgeX Product is being distributed, sold, or administered to humans (including,
in each case, for the purpose of obtaining any required regulatory approvals) by AgeX, or an Affiliate thereof, AgeX will, at
its sole cost and expense, procure and maintain commercial general liability insurance issued by an insurance carrier with an
A.M. Best rating of A or better in amounts not less than [***]. AgeX will have the Indemnitees named as additional insureds under
such insurance. All rights of subrogation will be waived against BioTime and its insurers. Such commercial general liability insurance
will provide (i) product liability coverage; (ii) broad form contractual liability coverage for AgeX’s indemnification under
this Agreement; and (iii) coverage for litigation costs. The specified minimum insurance amounts will not constitute a limitation
on AgeX’s obligation to indemnify the Indemnitees under this Agreement.

 

15.2
Evidence of Insurance and Notice of Changes. AgeX will provide BioTime with written evidence of such insurance upon request
of BioTime. AgeX will provide BioTime with written notice of at least [***] prior to the cancellation, non-renewal, or material
change in such insurance.

 

15.3
Continuing Insurance Obligations. AgeX will maintain such commercial general liability insurance beyond the expiration
or termination of this Agreement during (i) the period that any AgeX Product(s) developed pursuant to this Agreement is being
commercially distributed or sold by AgeX, any Affiliate thereof, or any agent of any of the foregoing; and (ii) for [***] after
such period.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

ARTICLE
16. WAIVER

 

No
waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed
a waiver as to any subsequent and/or similar breach or default.

 

ARTICLE
17. ASSIGNABILITY

 

Neither
this Agreement, nor any rights or obligations hereunder, are assignable or otherwise transferable, in whole or in part (including
by operation of law, merger, or other business combination), by AgeX without the prior written consent of BioTime. The failure
of AgeX to comply with the terms of this paragraph shall be grounds for termination of the Agreement by BioTime under Section
_. Any permitted assignee of either Party shall, as a condition to such assignment, assume all obligations of its assignor arising
under this Agreement following such assignment. Any purported assignment by a party of this Agreement, or any of such party’s
rights or obligations hereunder, in violation of this Article 17 shall be void. In the event of any assignment of this Agreement
by a party requiring the other party’s consent under this ARTICLE 17, the assigning Party shall pay the other Party [***]
upon the consummation of such assignment. In the event that written consent is provided by BioTime for the assignment of this
Agreement in connection with, (a) assignment of this Agreement by AgeX pursuant to this ARTICLE 17, or (b) any sale by AgeX of
all or substantially all of a portion of its assets or business constituting a particular AgeX Product line or business unit engaged
in the Research, Development or Commercialization of any AgeX Product, AgeX will pay BioTime a non-refundable fee of [***]. A
Change of Control will not be deemed an assignment.

 

ARTICLE
18. INDEMNIFICATION; LIMITATION OF LIABILITY

 

18.1
Indemnity by AgeX. AgeX shall indemnify, defend and hold harmless BioTime, its Affiliates (other than AgeX and AgeX’s
subsidiaries), and their respective officers, directors, employees and agents (each a “BioTime Indemnified Party”),
from and against any and all Claims arising from or occurring as a result of the death or injury of any person caused or resulting
(or allegedly caused or resulting) from the use of any AgeX Product:

 

(a)
any default by AgeX of its obligations under this Agreement;

 

(b)
any breach by AgeX of any of its representations and warranties set forth in this Agreement; and

 

(c)
any negligent act or omission of AgeX in connection with the performance of its obligations under this Agreement;

 

Notwithstanding
the foregoing, AgeX shall not be required to indemnify BioTime, its Affiliates, and their respective officers, directors, employees
and agents for any Claim to the extent such Claim are attributable to any of the matters as to which BioTime has an obligation
to indemnify AgeX or for which the negligence, willful misconduct, or violation of any law by any Person other than AgeX an AgeX
Indemnified Party contributed to the death or injury that is the subject of the Claim.

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

18.2
Indemnity by BioTime. BioTime shall indemnify, defend and hold harmless AgeX, its subsidiaries and their respective officers,
directors, employees and agents, from and against any and all costs, claims, damages and expenses (including reasonable attorneys’
fees and other expenses of legal proceedings) (collectively, “Claims”), in connection with any and all
suits, actions, investigations, claims or demands of Third Parties arising from or occurring as a result of death or injury of
any person caused or resulting from the use of any BioTime Product. Notwithstanding the foregoing, BioTime shall not be required
to indemnify AgeX, its Affiliates, and their respective officers, directors, employees and agents for any Claims to the extent
such Claims are attributable to any of the matters as to which AgeX has an obligation to indemnify BioTime or for which AgeX’s
negligence or willful misconduct contributed to the Claim.

 

18.3
Indemnification Procedures.

 

a)
Notice of Claim. In the event of any claim, action or proceeding for which a Person is entitled to indemnity hereunder,
the Person seeking indemnity (“Claimant”) shall promptly notify the relevant Party (“Indemnitor”)
of such matter in writing, but in no event shall the Indemnitor be liable for any Claim that result from any delay in providing
such notice.

 

b)
Control of Defense. As its option, Indemnitor may then assume responsibility for and shall have full control of such matter
by giving notice to Claimant within thirty (30) days after the Indemnitor’s receipt of notice from Claimant. The assumption
of the defense of a Claim by the Indemnitor shall not be construed as an acknowledgment that Indemnitor is liable to indemnify
Claimant in respect of the Third Party claim, nor shall it constitute a waiver by Indemnitor of any defenses it may assert against
Claimant’s claim for indemnification. Upon assuming the defense of a Third Party claim, Indemnitor may appoint as lead counsel
in the defense of the Claim any legal counsel selected by Indemnitor. In the event Indemnitor assumes the defense of a Third Party
claim, Claimant shall immediately deliver to Indemnitor all original notices and documents (including court papers) received by
Claimant in connection with the Third Party claim. Should Indemnitor assume the defense of a Third Party claim, except as provided
below, Indemnitor shall not be liable to Claimant for any legal expenses subsequently incurred by such Claimant in connection
with the analysis, defense or settlement of the Third Party claim. In the event that it is ultimately determined that Indemnitor
is not obligated to indemnify, defend or hold harmless Claimant from and against the Third Party claim, Claimant shall reimburse
Indemnitor for any and all costs and expenses (including attorneys’ fees and costs of suit) and any Third Party claims incurred
by Indemnitor in its defense of the Third Party claim. Without limiting the foregoing, any Claimant shall be entitled to participate
in, but not control, the defense of such Claim and to employ counsel of its choice for such purpose; provided, however,
that such employment shall be at Claimant’s own expense unless (a) the employment thereof has been specifically authorized
by Indemnitor in writing, (b) Indemnitor has failed to assume the defense and employ counsel in accordance with this Section 14.4.2
(in which case Claimant shall control the defense) or (c) the interests of Claimant and Indemnitor with respect to such Claim
are sufficiently adverse to prohibit the representation by the same counsel of both Parties under applicable law, ethical rules
or equitable principles.

 

    	 

    	Execution Version

    

 

c)
Settlement. With respect to any Claim relating solely to the payment of money damages in connection with a Claim and that
shall not result in Claimant’s becoming subject to injunctive or other relief or otherwise adversely affecting the business
of Claimant in any manner, and as to which Indemnitor shall have acknowledged in writing the obligation to indemnify Claimant
hereunder, Indemnitor shall have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise
dispose of such Claim, on such terms as Indemnitor, in its sole discretion, shall deem appropriate. With respect to all other
Claim, where Indemnitor has assumed the defense of the Claim in accordance with Section 9.4(b), Indemnitor shall have authority
to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Claim, provided it obtains
the prior written consent of Claimant (which consent shall not be unreasonably withheld or delayed). Indemnitor shall not be liable
for any settlement or other disposition of a Claim by Claimant that is reached without the written consent of Indemnitor. Regardless
of whether Indemnitor chooses to defend or prosecute any Third Party claim, no Claimant shall admit any liability with respect
to or settle, compromise or discharge, any Claim without the prior written consent of Indemnitor, such consent not to be unreasonably
withheld or delayed.

 

d)
Cooperation. Regardless of whether Indemnitor chooses to defend or prosecute any Third Party claim, Claimant shall cooperate
in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend
such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection therewith.
Such cooperation shall include access during normal business hours afforded to Indemnitor to, and reasonable retention by Claimant
of, records and information that are reasonably relevant to such Third Party claim, and making employees and agents available
on a mutually convenient basis to provide additional information and explanation of any material provided hereunder, and Indemnitor
shall reimburse Claimant for all its reasonable out-of-pocket expenses in connection therewith.

 

e)
Expenses. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by Claimant
in connection with any claim shall be reimbursed on a calendar quarter basis by Indemnitor, without prejudice to Indemnitor’s
right to contest Claimant’s right to indemnification and subject to refund in the event Indemnitor is ultimately held not
to be obligated to indemnify Claimant.

 

18.4
Limitation of Liability. UNDER NO CIRCUMSTANCES SHALL A PARTY HERETO BE LIABLE TO THE OTHER PARTY FOR CONSEQUENTIAL, INCIDENTAL,
PUNITIVE OR SPECIAL DAMAGES IN RESPECT OF PERFORMANCE OF THIS AGREEMENT; PROVIDED, HOWEVER, THAT ALL AMOUNTS THAT AN INDEMNIFIED
PERSON IS REQUIRED TO PAY TO ANY THIRD PARTY AS THE RESULT OF A MATTER FOR WHICH SUCH INDEMNIFIED PERSON IS ENTITLED TO BE INDEMNIFIED
UNDER THIS ARTICLE SHALL BE CONSIDERED TO BE DIRECT DAMAGES WHICH ARE INDEMNIFIABLE HEREUNDER.

 

    	 

    	Execution Version

    

 

ARTICLE
19. NOTICES

 

Any
payment, notice or other communication required or permitted to be given to either party hereto shall be in writing and shall
be deemed to have been properly given and effective: (a) on the date of delivery if delivered in person during recipient’s
normal business hours; or (b) on the date of attempted delivery if delivered by courier, express mail service or first-class mail,
registered or certified. Such notice shall be sent or delivered to the respective addresses given below, or to such other address
as either party shall designate by written notice given to the other party as follows:

 

In
the case of AgeX:

 

AgeX
Therapeutics, Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention: Michael D. West, Ph.D., CEO

Email: mwest@biotimeinc.com

 

In
the case of BioTime:

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention:
Aditya Mohanty, CO-CEO

Email:
amohanty@biotimeinc.com

 

and

 

BioTime,
Inc.

1010
Atlantic Avenue, Suite 102

Alameda,
CA 94501

Attention:
General Counsel

Email:
legal@biotimeinc.com

 

ARTICLE
20. REGULATORY COMPLIANCE

 

20.1
Registration of Agreement. When required by local/national law, AgeX shall register this Agreement, pay all costs and legal
fees connected therewith, and otherwise insure that the local/national laws affecting this Agreement are fully satisfied.

 

20.2
Compliance With Law. AgeX shall comply, and shall ensure that its Affiliates comply, with all applicable laws, rules and
regulations in the exercise of its rights and performance of its obligations hereunder, including but not limited to all laws,
rules, and regulations concerning the export and/or management of technology or information. AgeX understands that the Arms Export
Control Act (“AECA”), including its implementing International Traffic In Arms Regulations (“ITAR”)
and the Export Administration Act (“EAA”), including its Export Administration Regulations (“EAR”),
are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations. AgeX further understands
that the U.S. export laws and regulations include (but are not limited to): (1) ITAR and EAR product/service/data-specific requirements;
(2) ITAR and EAR ultimate destination-specific requirements; (3) ITAR and EAR end user-specific requirements; (4) ITAR and EAR
end use-specific requirements; (5) Foreign Corrupt Practices Act; and (6) anti-boycott laws and regulations. AgeX will comply
with all then-current applicable export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations)
pertaining to the AgeX Product(s) (including any associated products, items, articles, computer software, media, services, technical
data, and other information). AgeX certifies that it will not, directly or indirectly, export (including any deemed export), nor
re-export (including any deemed re-export) the AgeX Product(s) (including any associated products, items, articles, computer software,
media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S.
laws and regulations.

 

    	 

    	Execution Version

    

 

ARTICLE
21. GOVERNING LAW

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of California, without giving effect to
any conflict of laws principles or rules.

 

ARTICLE
22. RELATIONSHIP OF PARTIES

 

In
assuming and performing the obligations of this Agreement, AgeX and BioTime are each acting as independent parties and neither
shall be considered or represent itself as a joint venture, partner, agent or employee of the other.

 

ARTICLE
23. USE OF NAMES

 

23.1
By AgeX. AgeX may not use the name of BioTime in connection with any name, brand or trademark related to Licensed Products,
Licensed Process or Licensed Services without prior written consent.

 

23.2
By BioTime. BioTime may not use AgeX’s name in connection with BioTime’s publicity related to their respective
intellectual property and commercialization achievements without prior written consent.

 

ARTICLE
24. DISPUTE RESOLUTION

 

24.1
Good Faith Discussions. In the event that any controversy or claim shall arise between the Parties under, out of, in connection
with, or relating to this Agreement or the breach thereof, the Party initiating such controversy or making such claim shall provide
to the other Party written notice containing a brief and concise statement of the initiating Party’s claims, together with
relevant facts supporting them. During a period of sixty (60) days, or such longer period as may be mutually agreed upon in writing
by the Parties, following the date of said notice, the Parties shall make good faith efforts to settle the dispute. Such efforts
may include, but shall not be limited to, full presentation of both Parties’ claims and responses, with or without the assistance
of counsel, before the chief executive officers (or their designees) of the Parties.

 

24.2
Arbitration. In the event that the Parties have been unable to reach accord using the procedures set forth in Section 13.1
and only if such is the case, either Party may seek final resolution of the matter through binding arbitration, and only through
binding arbitration. The failure of a Party to comply with the provisions of Section 13.2 with respect to any controversy or claim
shall constitute an absolute bar to the institution of any proceedings, by arbitration or otherwise, with respect to such controversy
or claim. Any such arbitration shall be held in San Francisco, California in the English language before a panel of three (3)
arbitrators in accordance with the then existing Rules of Arbitration of the American Arbitration Association (the “AAA”)
and judgment upon the award rendered by the arbitrators may be entered or enforced in any court having jurisdiction thereof. In
any arbitration proceeding hereunder, each Party shall select one arbitrator and the arbitrators selected by the Parties shall
then select a third arbitrator, who shall have at least fifteen (15) years’ experience in pharmaceutical patent licensing.
The arbitrators shall permit the Parties to have discovery to the extent permitted by the rules of the AAA. The decision of the
arbitrators shall be final and binding on the Parties and shall be accompanied by a written opinion of the arbitrators explaining
the arbitrators’ rationale for their decision. The intent of the Parties is that except for the entering of an arbitration
order in a court of competent jurisdiction, disputes shall be resolved finally in arbitration as provided above, without appeal,
and without recourse to litigation in the courts.

 

    	 

    	Execution Version

    

 

24.3
Exceptions. Notwithstanding the foregoing provisions of Sections 13.1 and 13.2, either Party may initiate an action before
any court having competent jurisdiction in order to obtain interim or conservatory relief, such as an order to preserve the status
quo and to avoid incurring irreparable harm pending the resolution of any dispute that is submitted to arbitration, to prevent
or enjoin a breach or threatened breach of confidentiality or to enforce provisions of this Agreement relating to ownership rights
in intellectual property without complying with the procedures set forth in Sections 25.1 and 25.2.

 

ARTICLE
25. GENERAL PROVISIONS

 

25.1
The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to
affect the meaning or interpretation of this Agreement.

 

25.2
This Agreement shall not be binding upon the parties until it has been signed herein below by or on behalf of each party, and
as of the Effective Date.

 

25.3
No amendment or modification of this Agreement shall be valid or binding upon the parties unless made in writing and signed by
both parties.

 

25.4
This Agreement embodies the entire understanding of the parties, and supersede all previous communications, representations or
understandings, either oral or written, between the parties relating to the subject matter thereof.

 

25.5
The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be
invalid or unenforceable under any controlling body of the law, such invalidity or unenforceability shall not in any way affect
the validity or enforceability of the remaining provisions hereof.

 

25.6
This Agreement may be signed in counterparts, each of which when taken together shall constitute one fully executed document.
Each individual executing this Agreement on behalf of a legal Person does hereby represent and warrant to each other person so
signing that he or she has been duly authorized to execute this Agreement on behalf of such Person.

 

25.7
In the event of any litigation, arbitration, judicial reference or other legal proceeding involving the parties to this Agreement
to enforce any provision of this Agreement, to enforce any remedy available upon default under this Agreement, or seeking a declaration
of the rights of either party under this Agreement, the prevailing party shall be entitled to recover from the other such attorneys’
fees and costs as may be reasonably incurred, including the costs of reasonable investigation, preparation and professional or
expert consultation incurred by reason of such litigation, arbitration, judicial reference, or other legal proceeding.

 

[Signature
page follows]

 

    	 

    	Execution Version

    

 

IN
WITNESS WHEREOF, BioTime and AgeX have executed this Agreement by their respective officers hereunto duly authorized, on the day
and year hereinafter written.

 

	AGEX
    THERAPEUTICS, INC.	 	BIOTIME,
    INC.
	 	 	 	 	 
	By	/s/
    Michael D. West	 	By	/s/
    Aditya P. Mohanty
		(Signature)	 	 	(Signature)
	Name:
    	Michael
    D. West	 	Name:
    	Aditya
    P. Mohanty
	Title:
    	Chief
    Executive Officer	 	Title:
    	Co-Chief
    Executive Officer

 

[Signature
page of the ACT Sublicense Agreement]

 

    	 

    	Execution Version

    

 

EXHIBIT
A

 

Cells
or Cell Lines

 

	ACT
    No.	 	Cell
    Line
	[***]	 	[***]

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

EXHIBIT
B 

 

	ACT
    No.	 	Cell
    Line
	[***]	 	[***]

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

    	 

    	Execution Version

    

 

EXHIBIT
C

 

Patent
Rights

 

[***]

 

[***]

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***],” HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.FIRST
AMENDMENT TO LICENSE AGREEMENT

 

THIS
FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into on November 8, 2017 (the “Effective
Date”) by and between BIOTIME, INC., a California corporation, having its principal place of business at 1010 Atlantic Avenue,
Suite 102, Alameda, CA 94501 (“BioTime”), and AGEX THERAPEUTICS, INC., a Delaware corporation, having
its principal place of business at 1010 Atlantic Avenue, Suite 102, Alameda, CA 94501 (“AgeX”).

 

WITNESSETH

 

WHEREAS,
the parties previously entered into a License Agreement (“Agreement”) on 17 August 2017 and now wish to clarify the
rights granted thereunder; and

 

NOW
THEREFORE, for and in consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree
as follows:

 

1. Section
1.3 of the Agreement shall be deleted and replaced in its entirety by:

 
  “AgeX Cellular Product” means any HyStem Product that contains a Therapeutic Cell.

 

2. Capitalized
terms used herein have the same meaning given to them in the Agreement.

 

3. Other
than expressly amended herein, the Agreement remains in full force and effect.

 

4. This
First Amendment may be executed in any number of counterparts.

 

[SIGNATURE
PAGE TO FOLLOW]

 

    	 

    	 

    

 

IN
WITNESS WHEREOF, BioTime and AgeX have executed this Agreement by their respective officers hereunto duly authorized, on the day
and year hereinafter written.

 

	AGEX
    THERAPEUTICS, INC.	 	BIOTIME,
    INC.
	 	 	 	 	 
	By:	/s/
    Michael D. West	 	By:	/s/
    Aditya P. Mohanty
	 	Michael
    D. West	 		Aditya P. Mohanty
	Title:	Chief
    Executive Officer	 	Title:	Co-Chief
    Executive Officer

 

[SIGNATURE
PAGE TO THE FIRST AMENDMENT TO THE HYSTEM SUBLICENSE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00285-of-00352.parquet"}]]